# A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).

> **NCT05620576** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 131 (actual)

## Conditions studied

- Diabetic Peripheral Neuropathic Pain

## Interventions

- **DRUG:** LY3857210
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05620576
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-14
- **Primary completion:** 2023-07-19
- **Final completion:** 2023-08-01
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05620576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05620576, "A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05620576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*